title: PharmGKB summary: voriconazole pathway, pharmacokinetics.
authors.affiliation: Departments of aBiomedical Data Science bBioengineering, Stanford University, Stanford, California cIcahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine dDepartment of Medicine, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai eDepartment of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Barbarino
authors.forename: Aniwaa
authors.initials: A
authors.lastname: Owusu Obeng
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
mesh_terms: D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001230:Aspergillus / Q000187:drug effects / Q000472:pathogenicity; D002175:Candida / Q000187:drug effects / Q000472:pathogenicity; D005670:Fusarium / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D010597:Pharmacogenetics; D021681:Scedosporium / Q000187:drug effects / Q000472:pathogenicity; D065819:Voriconazole / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D065819:Voriconazole